Ji Yuan, Chadha Arsheen, Krity Abhash, Huang Shenglan
Changzhou Medical Centre, Nanjing Medical University, Changzhou, Jiangsu, China.
Department of Cardiology, Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, Changzhou, Jiangsu, China.
Front Endocrinol (Lausanne). 2025 Aug 13;16:1553173. doi: 10.3389/fendo.2025.1553173. eCollection 2025.
Despite positive impacts of lipid-lowering therapies (LLTs), the low-density lipoprotein cholesterol (LDL-C) target attainment remains suboptimal. This study aimed to investigate LDL-C goal achievement per the 2023 China guideline for lipid management among rehospitalized hypertriglyceridemia patients, who had higher chances to access the knowledge associated with lipid management and treatment, and evaluate the risk factors for LDL-C.
This retrospective study was performed among rehospitalized hypertriglyceridemia patients between July 2020 and May 2023. The department-specific latent class trajectory modeling was implemented to assess the longitudinal lipid profiles. The risk factors of goal attainment were evaluated using multivariate Cox regression analysis.
Among 8905 readmitted patients, 5045 (56.7%) had two admissions. Only 27.1% consistently achieved LDL-C targets, while 25% never did. Nearly half were eligible for LLTs, but only 25% received them. Continuous LLT use was associated with higher goal attainment (HR: 1.23 [95% CI: 1.12-1.36]). Most readmissions (92.15%) had increasing LDL-C trajectories and less odds of achieving the LDL goals at the last hospitalization. At the latest hospitalization, patients with higher atherosclerotic cardiovascular disease (ASCVD) risk had higher chances of achieving their LDL-C targets (hazard ratio 2.00 [95% CI, 1.70-2.36]).
LDL-C control remains poor in this population. Continuous LLT use and ASCVD risk stratification are important factors for goal attainment, highlighting the need for better long-term management and closer monitoring of low-risk patients.
尽管降脂治疗(LLTs)具有积极作用,但低密度脂蛋白胆固醇(LDL-C)目标达成情况仍不尽人意。本研究旨在调查2023年中国血脂管理指南中再次住院的高甘油三酯血症患者的LDL-C目标达成情况,这些患者有更多机会获取血脂管理和治疗相关知识,并评估LDL-C的危险因素。
本回顾性研究在2020年7月至2023年5月再次住院的高甘油三酯血症患者中进行。采用科室特异性潜在类别轨迹模型评估纵向血脂谱。使用多变量Cox回归分析评估目标达成的危险因素。
在8905例再次入院患者中,5045例(56.7%)有两次入院记录。仅有27.1%的患者始终达到LDL-C目标,而25%的患者从未达到。近一半患者符合降脂治疗条件,但只有25%接受了治疗。持续使用降脂治疗与更高的目标达成率相关(风险比:1.23 [95%置信区间:1.12 - 1.36])。大多数再次入院患者(92.15%)的LDL-C轨迹呈上升趋势,且在上次住院时达到LDL目标的几率较低。在最近一次住院时,动脉粥样硬化性心血管疾病(ASCVD)风险较高的患者达到LDL-C目标的几率更高(风险比2.00 [95%置信区间,1.70 - 2.36])。
该人群中LDL-C控制情况仍然较差。持续使用降脂治疗和ASCVD风险分层是目标达成的重要因素,这凸显了对低风险患者进行更好的长期管理和密切监测的必要性。